Strategic partnerships with enterprise networks could sustain BrainsWay's growth as its installed base expands beyond 2,000 systems.
BWAY Brainsway Ltd.
XNAS
10.11
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BWAY
$10.11
—
What changed
Recent filings, trades and movesKey stats
$10.11
- 52-Week Range
- $7.13 – $17.40
- YTD
- +4.82%
- IV Rank (30D)
- 34.66
- Straddle Price
- $4.10
- P/C Vol Ratio
- 0.26
- Market Cap
- $0.4B
- Open
- $10.31
- Day Range
- $9.71 – $10.31
- Volume
- 183,578
- Prev Close
- $10.25
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.88% |
| Beta vs SPY | 1.18 |
| Cost of Equity (CAPM) | 11.40% (VRP-adj) |
| WACC | 11.50% |
| Volatility Risk Premium | +122.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Book / Price | 17.7% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $12.35 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $11.33 |
| Bollinger Width / SMA20 | 16.2% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: ABBV, ACAD, ACHC, BTSG, DFTX, JNJ, LFST, MPLT
60-Day Conviction
39%
20-Day Fair Value
≈ by Dec 14, 2026
$10.16
α +0.5%
rank 64%
conviction
42%
40-Day Fair Value
≈ by Jan 12, 2027
$10.47
α +3.6%
rank 59%
conviction
86%
60-Day Fair Value
≈ by Feb 10, 2027
$10.25
α +1.4%
rank 52%
conviction
39%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 41.9× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 21.2× · 6 peers |
| Peer P/B | $6.65 | 18% | median 3.7× · 7 peers |
| Peer P/S | n/a | 0% | median 3.0× · 6 peers |
| Market Anchor (SMA50) | $12.35 | 82% | stability 69% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-13 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.4B
- Employees
- 129
- List Date
- 2019-04-17
- CIK
- 0001505065
- Homepage
- https://www.brainsway.com
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives re…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 12.29% | 0.39% | -11.45% | -13.30% | 9.71% | 21.20% | 3.14% |
| Feb | 7.01% | -1.46% | -5.83% | 12.11% | -4.02% | -0.47% | 1.22% |
| Mar | 1.01% | 11.21% | -9.07% | -19.36% | 1.45% | 12.20% | -0.43% |
| Apr | -8.00% | -12.44% | -13.89% | -4.72% | -5.66% | 21.94% | -3.79% |
| May | 28.19% | -4.67% | 12.50% | 13.13% | 15.78% | -5.64% | 9.88% |
| Jun | -7.27% | -28.23% | 31.03% | -8.31% | 28.67% | 0.45% | 2.72% |
| Jul | -12.16% | 25.51% | 8.48% | 23.55% | -9.98% | -0.78% | 5.77% |
| Aug | -11.78% | -31.20% | 48.07% | 13.49% | 35.66% | -8.16% | 7.68% |
| Sep | 1.13% | -10.64% | 14.77% | 24.03% | -1.12% | -7.50% | 3.45% |
| Oct | -0.61% | -5.89% | -11.63% | 10.38% | 10.93% | -9.84% | -1.11% |
| Nov | -9.12% | -46.47% | 71.78% | -3.52% | 0.63% | -8.84%* | 0.74% |
| Dec | 1.45% | 33.51% | -0.92% | -4.84% | 12.08% | -- | 8.26% |
| Total | -4.68% | -65.80% | 166.87% | 36.53% | 126.82% | 8.37% | 44.69% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $11.27
SMA 50: $12.26
SMA 200: $13.87
Current: $10.11
EMA 12: $10.94
EMA 26: $11.41
MACD: -0.4739 | Signal: -0.0392
BEARISH
ADX (14): 17.67
RANGE
+DI: 16.91
−DI: 30.20
Momentum Oscillators
RSI (14): 37.45
NEUTRAL
Stoch %K: 22.89
Stoch %D: 31.37
Williams %R: -84.25
Volume & Volatility
BB Upper: $12.32
BB Lower: $10.21
OVERSOLD
OBV: 5,412,725
Vol SMA 20: 122,093
Vol ROC: 48.20%
ATR: $0.70
True Range: $0.60
HV 20: 70.4%
HV 30: 62.2%
HV 60: 47.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-15T00:00:00 – 2026-11-13T00:00:00
AI Analysis
LLM Stock Analysis Report - BWAY
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers: FDA clearance, positive news sentiment, and technical momentum signals.
Primary risks: High volatility, potential for overbought conditions, and market uncertainty.
Investment thesis: BWAY is poised to continue its upward trend driven by recent FDA clearance and positive news sentiment. However, the high volatility and potential for overbought conditions may pose risks to the investment thesis.
Recent news sentiment impact: The recent news headlines have been mostly positive, with the FDA clearance of Deep TMS as an adjunct therapy for MDD in adolescents aged 15-21 being a significant catalyst.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish; Medium-term (1-3 months): Neutral to Bullish; Long-term (3-12 months): Bullish
Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- SMA 20: $15.49 (support)
- SMA 50: $15.07 (support)
- SMA 200: $12.59 (resistance)
- EMA 12: $15.52 (support)
- EMA 26: $15.41 (support)
Momentum Signals:
- RSI interpretation: Neutral (49.42) - not overbought or oversold
- MACD signal: Bullish (0.11 / Signal: -0.03 / Histogram: 0.13)
- Bollinger Bands position: Neutral
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 137229.20 ( declining trend)
- On-Balance Volume (OBV): 9703153.42 (neutral to positive)
- Volume Rate of Change: -81.29% (negative)
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles:
- FDA clearance for Deep TMS as adjunct therapy for MDD in adolescents aged 15-21
- Grant from National Institutes of Health to investigate accelerated Deep TMS for treatment of alcohol use disorder
- Positive sentiment from recent earnings reports and analyst upgrades
Sentiment Assessment: Aggregate news sentiment: POSITIVE (6/10)
Catalyst Identification: Upcoming events:
- BrainsWay's second-quarter financial results on August 12, 2026
- FDA clearance for Deep TMS as adjunct therapy for MDD in adolescents aged 15-21
Market Narrative: How news aligns with or contradicts technical signals:
- Technical momentum signals align with positive news sentiment and recent FDA clearance.
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market: HIGH (beta >1.86)
Volatility Regime: Current vs historical volatility levels:
- Historical Volatility: HV20 73.2%, HV30 66.3%, HV60 56.8%
- Current Volatility: 0.55 (high)
Options Market Signals:
- IV Rank: 27.9% (Medium)
- Current IV: 135.2% (high)
- Expected Move: $5.00 (39 DTE), 7-DTE: $3.10
- Volume Flow: 2 calls vs 1 puts
- Open Interest: 2 calls vs 1 puts
Downside Protection: Support levels and risk management considerations:
- SMA 20: $15.49 (support)
- SMA 50: $15.07 (support)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- Strong performance in the healthcare sector, driven by positive sentiment and recent FDA clearance.
Institutional Activity: Volume patterns suggesting institutional interest signals:
- Institutional buying pressure evident in increasing volume flow and open interest.
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- R-squared: 0.43 - the stock is moderately correlated with the market.
Relative Valuation: Position within trading range:
- BWAY is currently trading above its short-term mean, indicating potential for further upside.
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- SMA 20: $15.49 (support)
- SMA 50: $15.07 (support)
- SMA 200: $12.59 (resistance)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- EMA 12: $15.52 (support)
- EMA 26: $15.41 (support)
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- BrainsWay's second-quarter financial results on August 12, 2026
- FDA clearance for Deep TMS as adjunct therapy for MDD in adolescents aged 15-21
Risk Management: Stop-loss levels and position sizing considerations:
- Set stop-loss at $14.50 (below SMA 20) to mitigate potential losses.
- Consider reducing position size or hedging strategy due to high volatility.
By analyzing the technical indicators, news sentiment, and risk metrics, we conclude that BWAY is poised for further upside driven by positive news sentiment and recent FDA clearance. However, the high volatility and potential for overbought conditions may pose risks to the investment thesis. It is essential to monitor critical price levels, breakout/breakdown levels, and time-sensitive catalysts while managing risk through stop-loss levels and position sizing considerations.
Generated
News
All BWAY news →
Shipments and recurring demand both climbed sharply this quarter.
BWAY Options Activity & IV Rank
BWAY IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 136.6%
7-DTE IV: —
Expected Move: $4.10
7-DTE Move: $4.30
Days to Exp: 35 (2026-12-18)
Options Flow · All expiries
Call Volume: 78
Put Volume: 20
P/C Volume: 0.256
BULLISH
Call OI: 352
Put OI: 3
P/C OI: 0.009
Total OI: 355
ATM Options Pricing
ATM Call: $2.05
ATM Put: $2.05
Call %: 20.3%
Put %: 20.3%
Chain Summary
Chain Volume: 98
Chain OI: 355
Last Updated: 11/13/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 14th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
14%
vs own history
GEX tilt
+0.24
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Put vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put
—
—
pts
EXTREME
as of Nov 13 · No data
30 DTE / 10d put
—
—
pts
EXTREME
as of Nov 13 · ATM 102.7% / Put —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)34.7MediumNov 13
Straddle Price (30 DTE)$4.10Nov 13
Beta Analysis
Risk Metrics
Beta: 2.0633
Alpha: 12.59%
Correlation: 0.5107
R-Squared: 26.1%
Stock Volatility: 55.1%
Market Volatility: 13.6%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own BWAY
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $7.4M | #1224 of 3138 | -8.2% | 13F | |
| Citadel Hedge fund Ken Griffin | $737K | #4043 of 6285 | -45.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BWAY Institutional Ownership (13F)
Filings for 2026-06-30 · 27 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 39,605,518 (as of 2025-12-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$170.61K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $170.61K | 100.00% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
BWAY Insider Trading (Form 4)
Latest: 2026-06-22Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | Gilad Moiseyev | Chief Technology Officer | Mixed Exer +7,500 · Sell −5,000 · Tax −1,902 |
+598 | — | EDGAR | |
| 2026-06-03 | Yiftach Roth | Chief Scientist | Sell (S) | −7,000 | — | EDGAR | |
| 2026-05-26 | Rayten Michal Ety Mitrany | Director | Sell (S) | −17,980 | — | EDGAR | |
| 2026-05-21 | Rayten Michal Ety Mitrany | Director | Mixed Exer +27,500 · Tax −9,520 |
+17,980 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BWAY Insider Holdings
3 insiders · @ $10.11
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Yiftach Roth | Chief Scientist | 1,072,305 | $10.84M | $0 | 1 | 2026-06-03 |
| 2 | Gilad Moiseyev | Chief Technology Officer | 58,098 | $587.4K | $0 | 1 | 2026-06-22 |
| 3 | Rayten Michal Ety Mitrany | Director | 20,480 | $207.1K | $0 | 2 | 2026-05-26 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
7 ETFs hold BWAY
7 shown · $1.82M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | ITEQ Amplify BlueStar Israel Technology ETF | Nport | 0.96% | $1.2M | — | 2026-06-30 |
| 2 | APIE ActivePassive International Equity ETF | Nport | 0.02% | $249,904 | — | 2026-08-31 |
| 3 | EHLS Even Herd Long Short ETF | Nport | 0.38% | $229,470 | — | 2026-06-30 |
| 4 | ISCF iShares International Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.01% | $97,267 | $708.9M | 2026-11-12 |
| 5 | IBRN iShares Neuroscience and Healthcare ETF | iShares (BlackRock) | 0.57% | $48,770 | $8.5M | 2026-11-12 |
| 6 | ASD Defiance Autism Impact ETF | Nport | 2.58% | $34,898 | — | 2026-06-30 |
| 7 | IZRL ARK Israel Innovative Technology ETF | ARK Invest | 1.45% | — | — | 2026-11-13 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (5 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '25 | 2025-12-31 | — | — | — | — |
| Q4 '24 | 2024-12-31 | — | — | — | — |
| Q4 '23 | 2023-12-31 | — | — | — | — |
| Q4 '22 | 2022-12-31 | — | — | — | — |
| Q4 '21 | 2021-12-31 | — | — | — | — |
Q4 2025 • period ending 2025-12-31 • filed 2026-04-20
BWAY vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| JNJ Johnson & Johnson | $682.5B | 43.4 | +7.8% | +37.8% | 65 |
| ABBV ABBVIE INC. | $520.5B | 50.8 | +10.7% | +28.7% | 26 |
| BTSG BrightSpring Health Services, Inc. Commo | $14.2B | 38.7 | +26.0% | +85.4% | 20 |
| LFST LifeStance Health Group, Inc. Common Sto | $5.4B | 74.1 | +22.6% | +102.3% | 13 |
| DFTX Definium Therapeutics, Inc. Common Share | $4.5B | — | — | +108.6% | 25 |
| ACHC Acadia Healthcare Company, Inc. | $3.5B | — | +4.5% | +164.4% | 25 |
| ACAD Acadia Pharmaceuticals Inc. | $3.1B | 9.0 | +14.8% | −28.7% | 7 |
| BWAY Brainsway Ltd. American Depositary Share | $413M | — | — | +4.8% | 35 |
| MPLT MapLight Therapeutics, Inc. Common Stock | $393M | — | — | −56.8% | 5 |
| Peer median | $4.9B | 43.4 | +12.8% | +61.6% | 22 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
199.35K
SI % of Float
0.50%
Days to Cover
2.48
Short Vol Ratio
28.3%
Free Float
—
Float %
—
Short interest 2026-10-30 • Short volume 2026-11-13